SIBAT-A Computerized Assessment Tool for Suicide Ideation and Behavior: Development and Psychometric Properties.

Objective: Most assessments of suicidal ideation and behavior (SIB) are limited by reliance on a single assessor, typically a clinician or patient, with scant detail on patient-related drivers of SIB and inability to detect rapid change in SIB. Furthermore, many techniques do not include a semistructured interview, increasing rater variability. The Suicide Ideation and Behavior Assessment Tool (SIBAT) addresses these limitations.
Design: More than 30 experts in scale development, statistics, and clinical management of suicidal patients collaborated over a greater than four-year period to develop the SIBAT. Input for content and validity was received from patients, clinicians, and regulatory authorities in the United States (US) and Europe. Psychometric properties of the SIBAT were evaluated in validation studies.
Results: The SIBAT is organized into eight independent patient- or clinician-rated modules with branching logic and scoring algorithms, which necessitates computerization. Patient-reported information is first captured in Modules 1 to 5. Thereafter, an experienced clinician reviews the patient's report, conducts a semistructured interview (Module 6), and assesses the patient's suicide risk (Module 7) and optimal antisuicide management (Module 8). Input from cognitive interviews of diverse adult, adolescent, and clinician participants was incorporated into the final version of the SIBAT. Psychometric testing demonstrated good inter-rater reliability (intraclass coefficient range: 0.68-0.82), intra-rater reliability (weighted-kappa range: 0.64-0.76), and concurrent validity with other instruments for assessing SIB.
Conclusion: Patient- and clinician-based assessments and the psychometric studies summarized in this report support the validity and reliability of the SIBAT for capturing critical information related to assessment of SIB in adolescents and adults at risk for suicide.
Competing Interests: DISCLOSURES: LA was an employee of Janssen Scientific Affairs, LLC at the time of this work and holds Johnson & Johnson stock. He is currently an employee of Denovo Biopharma, San Diego, CA. D-JF, CJ, and CMC are employees of Janssen Research and Development, LLC or Janssen Scientific Affairs, LLC, and are stockholders of Johnson & Johnson. DW was an employee of Janssen Scientific Affairs, LLC at the time of this work and holds Johnson & Johnson stock. He has current affiliations with the Departments of Psychiatry and Neurology at University of South Alabama College of Medicine in Mobile, Alabama and Department of Psychiatry and Health Behavior at Augusta University in Augusta, Georgia. JHG is CEO of Healthcare Technology Systems, which receives royalties for use of the electronic Columbia-Suicide Severity Rating Scale (eC-SSRS). MH was an employee of PatientsLikeMe at the time of this work and is currently employed by Pfizer, Inc. J-PL has received research funding from Roche, Takeda, Neurocrine, Avanir, Jazz, and Lundbeck. CM has been a paid consultant to Janssen and AssureRx, is on the scientific board of Clarigent Health, and is the CEO of WeftHealth LLC. DVS is the author and copyright holder of the Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure (S-STS CMCM) mentioned in this manuscript, and he was a Continued on page 37 Continued from page 36 paid consultant to Janssen and has received royalties from Janssen for the use of his other scales and structured diagnostic interviews in their research studies. RCS has received grants from Acadia Pharmaceuticals; Alkermes, Inc.; Allergan, PLC; Assurex, Inc.; Avanir Pharmaceuticals, Inc.; Cerecor, Inc.; Intracellular Therapies; Janssen Pharmaceuticals; LivaNova, PLC; Navitor Pharmaceuticals; NeuroRx Inc.; Novartis Pharmaceuticals; Otsuka America; and Takeda Pharmaceuticals and has been a consultant for Acadia Pharmaceuticals; Allergan, PLC; Alfasigma USA, Inc.; Myriad Neuroscience; Novartis International AG; Evecxia Therapeutics; Seelos Therapeutics; Sunovion Pharmaceuticals, Inc.; NeuroRx, Inc.; and Seelos Therapeutics. PW was an employee of PatientsLikeMe at the time of this work and is employed by Wicks Digital Health Ltd., which has received funding from Ada Health, AstraZeneca, Baillie Gifford, Bold Health, Camoni, Compass Pathways, Coronna, EIT, Happify, Health Unlocked, Inbeeo, Kheiron Medical, Sano Genetics, Self Care Catalysts, The Learning Corp, The Welcome Trust, VeraSci, and Woebot.
(Copyright © 2022. Matrix Medical Communications. All rights reserved.)